Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 11Stomach Neoplasms 10Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 5Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2HER2-positive Gastric Cancer 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Neoplasms 1Muscle Invasive Bladder Carcinoma 1Muscle Invasive Bladder Cancer (MIBC) 1Muscle Invasive Bladder Cancer 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1Lung Neoplasms 1High-risk Non-muscle Invasive Bladder Cancer 1Head and Neck Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-low Breast Cancer 1Gastric Adenocarcinoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Biliary Tract Neoplasms 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × disitamab vedotin × Clear all
NCT06558682 2025-04-01

Neoadjuvant Therapy in Cervical Cancer

Qilu Hospital of Shandong University

Phase NA Recruiting
48 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06155396 2024-02-28

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
116 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡